GT
REGN icon

Glenview Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Glenview Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
4,404
+436
+11% +$297K 0.04% 208
2026
Q1 		$3.07M Sell
3,968
-3
-0.1% -$2.3K 0.05% 195
2025
Q4 		$3.07M Buy
3,971
+3
+0.1% +$2.04K 0.05% 194
2025
Q3 		$2.23M Sell
3,968
-10
-0.3% -$5.65K 0.04% 217
2025
Q2 		$2.09M Buy
3,978
+463
+13% +$258K 0.04% 214
2025
Q1 		$2.23M Buy
3,515
+444
+14% +$305K 0.04% 203
2024
Q4 		$2.19M Buy
3,071
+25
+0.8% +$21K 0.04% 198
2024
Q3 		$3.2M Hold
3,046
– – 0.06% 171
2024
Q2 		$3.2M Sell
3,046
-3
-0.1% -$2.91K 0.06% 164
2024
Q1 		$2.93M Hold
3,049
– – 0.06% 169
2023
Q4 		$2.68M Sell
3,049
-38
-1% -$31.3K 0.07% 171
2023
Q3 		$2.54M Buy
3,087
+29
+0.9% +$22.8K 0.07% 157
2023
Q2 		$2.2M Sell
3,058
-31
-1% -$23.9K 0.06% 171
2023
Q1 		$2.54M Hold
3,089
– – 0.08% 158
2022
Q4 		$2.23M Buy
3,089
+205
+7% +$151K 0.07% 158
2022
Q3 		$1.99M Buy
2,884
+333
+13% +$210K 0.08% 151
2022
Q2 		$1.51M Buy
2,551
+23
+0.9% +$14.9K 0.06% 167
2022
Q1 		$1.77M Sell
2,528
-1
-0% -$633 0.06% 164
2021
Q4 		$1.6M Sell
2,529
-105
-4% -$64.6K 0.05% 170
2021
Q3 		$1.59M Buy
2,634
+25
+1% +$15.5K 0.06% 162
2021
Q2 		$1.46M Buy
2,609
+150
+6% +$76K 0.06% 168
2021
Q1 		$1.16M Sell
2,459
-24
-1% -$11.7K 0.05% 178
2020
Q4 		$1.2M Sell
2,483
-12
-0.5% -$6.48K 0.06% 167
2020
Q3 		$1.4M Sell
2,495
-775
-24% -$470K 0.07% 152
2020
Q2 		$2.04M Buy
3,270
+10
+0.3% +$5.68K 0.12% 123
2020
Q1 		$1.59M Buy
3,260
+45
+1% +$18.6K 0.11% 131
2019
Q4 		$1.21M Buy
3,215
+820
+34% +$276K 0.07% 167
2019
Q3 		$664K Buy
2,395
+1,165
+95% +$345K 0.04% 212
2019
Q2 		$385K Buy
+1,230
New +$409K 0.02% 258

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Glenview Trust's REGN Position: Q2 2026 in Review

Glenview Trust increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, buying an estimated $297K and bringing the position to 4,404 shares worth $2.75M. The position accounts for 0.04% of the portfolio, ranked #208.

Glenview Trust first reported a position in REGN in Q2 2019 and has held it in 29 quarters since. The position peaked at $3.2M in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Glenview Trust held 4,404 shares of Regeneron Pharmaceuticals worth $2.75M as of Q2 2026.
  • Glenview Trust bought 436 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $297K.
  • Regeneron Pharmaceuticals made up 0.04% of Glenview Trust's portfolio in Q2 2026, its #208 holding.
  • Glenview Trust first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Glenview Trust's Regeneron Pharmaceuticals position peaked at $3.2M in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Glenview Trust's 13F filing for Q2 2026, filed 11 Aug 2026.